Search Within

Donna Mastey

Formats
  1. Meeting Abstract (8)
  2. Journal Article (3)
  3. Research Letter (2)
Groups
  1. Center for Hematologic Malignancies (13)
  2. Department of Medicine (13)
  3. Hematologic Malignancies Research (13)
  4. Hematologic Malignancies, Division of (13)
  5. Myeloma (13)
  6. Nursing (13)

More Groups

People
  1. Alexander Lesokhin (13)
  2. Carl Landgren (12)
  3. Meghan Salcedo (12)
  4. Hani Hassoun (11)
  5. Malin Hultcrantz (11)
  6. Neha Korde (11)

More People

Years
  1. 2023 (1)
  2. 2021 (3)
  3. 2020 (2)
  4. 2019 (3)
  5. 2018 (3)
  6. 2017 (1)
Publications
  1. Blood (7)
  2. American Journal of Hematology (1)
  3. Blood Advances (1)
  4. Clinica Chimica Acta (1)
  5. Clinical Lymphoma, Myeloma and Leukemia (1)
  6. Journal of Clinical Oncology (1)

More Publications

Publishers
  1. American Society of Hematology (8)
  2. Elsevier Inc. (2)
  3. American Society of Clinical Oncology (1)
  4. Elsevier Science BV (1)
  5. John Wiley & Sons, Inc. (1)

Results (13)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Association of patient activity bio-profiles with health-related quality of life in patients with newly diagnosed multiple myeloma: A prospective observational cohort study
    Journal Article

    Korde, N.; Tavitian, E.; Mastey, D.; Lengfellner, J.; Hevroni, G.; Zarski, A.; Salcedo, M.; Mailankody, S.; Hassoun, H.; Smith, E. L.; more...
    eClinicalMedicine (2023)

    Fulltext@MSK | Save
  • Using mobile wearables to establish sleep bioprofiles in newly diagnosed multiple myeloma (MM) patients
    Meeting Abstract

    Hevroni, G.; Mastey, D.; Tavitian, E.; Derkach, A.; Salcedo, M.; Mailankody, S.; Hassoun, H.; Lesokhin, A. M.; Smith, E. L.; Hultcrantz, M.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Tailored treatment to MRD response: A phase I/II study for newly diagnosed multiple myeloma patients using high dose twice-weekly carfilzomib (45 and 56 mg/m2) in combination with lenalidomide and dexamethasone
    Research Letter

    Korde, N.; Mastey, D.; Tavitian, E.; Mailankody, S.; Lesokhin, A.; Hassoun, H.; Smith, E. L.; Lendvai, N.; Hultcrantz, M.; Shah, U.; more...
    American Journal of Hematology (2021)

    Fulltext@MSK | Save
  • Using MALDI-TOF mass spectrometry in peripheral blood for the follow up of newly diagnosed multiple myeloma patients treated with daratumumab-based combination therapy
    Journal Article

    Eveillard, M.; Korde, N.; Ciardiello, A.; Diamond, B.; Lesokhin, A.; Mailankody, S.; Smith, E.; Hassoun, H.; Hultcrantz, M.; Shah, U.; more...
    Clinica Chimica Acta (2021)

    Fulltext@MSK | Save
  • Long-term sustained minimal residual disease (MRD) negativity in patients with multiple myeloma treated with continuous lenalidomide maintenance therapy: A clinical and correlative phase 2 study
    Meeting Abstract

    Diamond, B.; Korde, N.; Lesokhin, A. M.; Smith, E. L.; Shah, U. A.; Mailankody, S.; Hultcrantz, M.; Hassoun, H.; Lu, S. X.; Tan, C.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Phase I study of selinexor, ixazomib, and low-dose dexamethasone in patients with relapsed or refractory multiple myeloma
    Research Letter

    Salcedo, M.; Lendvai, N.; Mastey, D.; Schlossman, J.; Hultcrantz, M.; Korde, N.; Mailankody, S.; Lesokhin, A.; Hassoun, H.; Smith, E.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2020)

    Fulltext@MSK | Save
  • Long-term sustained minimal residual disease (MRD) negativity in multiple myeloma patients treated with lenalidomide maintenance therapy: A clinical and correlative phase 2 study
    Meeting Abstract

    Landgren, O.; Mastey, D.; Lesokhin, A. M.; Smith, E. L.; Shah, U. A.; Mailankody, S.; Hultcrantz, M.; Hassoun, H.; Lu, S. X.; Salcedo, M.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Weekly carfilzomib, lenalidomide, dexamethasone and daratumumab (wKRd-D) combination therapy provides unprecedented MRD negativity rates in newly diagnosed multiple myeloma: A clinical and correlative phase 2 study
    Meeting Abstract

    Landgren, O.; Hultcrantz, M.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; Smith, E. L.; Shah, U. A.; Lu, S. X.; Mastey, D.; Salcedo, M.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Minimal residual disease negativity in multiple myeloma is associated with intestinal microbiota composition
    Journal Article

    Pianko, M. J.; Devlin, S. M.; Littmann, E. R.; Chansakul, A.; Mastey, D.; Salcedo, M.; Fontana, E.; Ling, L.; Tavitian, E.; Slingerland, J. B.; more...
    Blood Advances (2019)

    Fulltext@MSK | Save
  • MRD-response driven phase I/II study for newly diagnosed multiple myeloma patients using higher doses of twice-weekly carfilzomib (45 and 56 mg/m(2)) in combination with lenalidomide and dexamethasone
    Meeting Abstract

    Korde, N.; Mastey, D.; Mailankody, S.; Hassoun, H.; Lesokhin, A. M.; Smith, E. L.; Lendvai, N.; Hultcrantz, M.; Tavitian, E.; Salcedo, M.; more...
    Blood (2018)

    Fulltext@MSK | Save